Sela Raises $21.0M Series A

Lilac Agriculture

Lilac is advancing a new generation of crop inoculants designed for real-world consistency, scalability, and yield. Spun out of research at North Dakota State University, our platform uses a practical, three-step approach to guide the evolution of inoculant products. We apply advanced genomic tools to enhance microbial efficacy and ensure competitiveness in the soil environment, addressing one of the biggest barriers to reliable on-farm performance.

Snorkel AI

Snorkel AI is the frontier AI data lab, helping teams build the data and environments behind high-performing frontier and agentic AI. We combine platform technology with research-driven data development to create datasets, benchmarks, evals, and custom solutions for real-world AI systems. Founded out of the Stanford AI Lab in 2019, Snorkel works with leading AI labs and enterprises to move from better data to better outcomes. Snorkel led the development of Senior SWE-Bench and launched Open Benchmarks Grants with a $3 million commitment to support open-source datasets, benchmarks, and evaluation research. Supported projects include Agents’ Last Exam, OSWorld 2.0, Terminal-Bench, Continual Learning Bench, and SlopCode Bench. Learn more at snorkel.ai or follow @SnorkelAI.

UltraSight

UltraSight aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. UltraSight’s AI-driven software provides real-time guidance and quality assessment to allow healthcare professionals, regardless of sonography proficiency, to consistently perform high-quality cardiac ultrasound in a variety of settings at the point of care, including clinics, community hospitals, ambulances, and remote and rural areas. UltraSight’s AI real-time guidance software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans. UltraSight’s software is an accessory to compatible general-purpose, diagnostic ultrasound systems. Full labeling is available at https://ultrasight.com/regulatory-approvals-and-labeling/. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices.